Eupraxia Pharmaceuticals Inc.
EPRX
$5.96
-$0.03-0.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 59.33% | 56.56% | 27.11% | 29.40% | 33.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.29% | 42.33% | -5.55% | -8.50% | -11.52% |
| Operating Income | -72.29% | -42.33% | 5.55% | 8.50% | 11.52% |
| Income Before Tax | -68.71% | -49.89% | -2.17% | -4.84% | 15.33% |
| Income Tax Expenses | 7,650.00% | 961.11% | -73.63% | -71.98% | -100.97% |
| Earnings from Continuing Operations | -68.82% | -49.96% | -2.07% | -4.74% | 15.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -80.20% | -87.77% | -92.84% | -88.58% | -83.37% |
| Net Income | -69.58% | -51.26% | -4.09% | -7.25% | 13.65% |
| EBIT | -72.29% | -42.33% | 5.55% | 8.50% | 11.52% |
| EBITDA | -72.32% | -42.32% | 5.71% | 8.66% | 11.58% |
| EPS Basic | -33.70% | -29.71% | 4.25% | 8.56% | 36.01% |
| Normalized Basic EPS | -31.28% | -23.69% | 10.08% | 12.18% | 37.55% |
| EPS Diluted | -33.70% | -29.71% | 4.25% | 8.56% | 36.01% |
| Normalized Diluted EPS | -31.28% | -23.69% | 10.08% | 12.18% | 37.55% |
| Average Basic Shares Outstanding | 26.85% | 17.78% | 13.19% | 21.84% | 37.55% |
| Average Diluted Shares Outstanding | 26.85% | 17.78% | 13.19% | 21.84% | 37.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |